about
The grass pollen season 2014 in Vienna: A pilot study combining phenology, aerobiology and symptom data.Coexistence of acute hearing loss with retinal artery occlusion and encephalopathy.Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis.Exhaled and nasal nitric oxide in laryngectomized patientsVirus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis.Cytokine patterns in nasal secretion of non-atopic patients distinguish between chronic rhinosinusitis with or without nasal polys.Eosinophils and mast cells: a comparison of nasal mucosa histology and cytology to markers in nasal discharge in patients with chronic sino-nasal diseases.Probiotics in the treatment of chronic rhinoconjunctivitis and chronic rhinosinusitis.Clinical use of adjuvants in allergen-immunotherapy.Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis.The grass pollen season 2015: a proof of concept multi-approach study in three different European cities.[Diagnosis and treatment of acute and chronic rhinosinusitis].[Allergic rhinitis: burden of disease].Correlation of three variables describing nasal patency (HD, MCA, NOSE score) in healthy subjects.Sensitization to common ragweed in southern Bavaria: clinical and geographical risk factors in atopic patients.In vitro diagnosis of chronic nasal inflammation.[Chronic rhinosinusitis and aspirin intolerance][Susac's syndrome. A rare microangiopathy of cochlea, retina, and brain].[Humoral mucosal immunity in allergic rhinitis]Microcrystalline Tyrosine (MCT®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.Elastography: a new diagnostic tool for evaluation of obstructive diseases of the salivary glands; primary results.Olfactory dysfunction in seasonal and perennial allergic rhinitis.Health-Related Quality of Life in rhino surgery.NARES: a risk factor for obstructive sleep apnea?Aluminium in allergen-specific subcutaneous immunotherapy--a German perspective.Analysis of aluminium in rat following administration of allergen immunotherapy using either aluminium or microcrystalline-tyrosine-based adjuvants.IgE reactivity profiles among house dust mite allergic patients in Bavaria.Real-Life Study for the Diagnosis of House Dust Mite Allergy - The Value of Recombinant Allergen-Based IgE Serology.Non-allergic rhinitis with eosinophilia syndrome is not associated with local production of specific IgE in nasal mucosa.Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.An approach of immunoneurological aspects in nasal allergic late phase.Occurrence of a terminal vascularisation after experimental myocardial infarction.Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapyDOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based VaccinesVaccination with nanoparticles combined with micro-adjuvants protects against cancerShortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen seasonVirus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases.[The sinobronchial syndrome. Assessment of the influence of the upper on the lower airway diseases]Nasal interleukin-5, immunoglobulin E, eosinophilic cationic protein, and soluble intercellular adhesion molecule-1 in chronic sinusitis, allergic rhinitis, and nasal polyposis
P50
Q31108847-5E9715F9-CB3A-40EE-8988-2F899CEE4E47Q33438080-C215273C-E32A-4606-9104-3FF1A3364B77Q33509671-B1D0790F-97B4-4E92-A5EB-6B2B8591BA45Q33526889-32A52FFE-1B75-41DB-B3CB-D172E8885B08Q33855899-64AEAFEF-0690-4384-8633-02F9ECC80DB2Q36086731-BE3BF3B3-FA2E-491B-8A19-C60F557A3C26Q36847376-BB698D03-B3DE-4B18-B387-D6A68C770863Q38083568-D911A5B4-A5E9-40A8-88DF-DF50601DF7BBQ38215758-3A3F4FAC-6B88-4817-8862-3BA98C3A4150Q38761412-3927FD1F-14BA-43FA-8423-C6C4C4C09DA2Q40135722-F924EF6E-4A94-4F06-AE4A-5AABBA628F81Q41279559-5F1AF756-B495-4E34-9910-4AD568BA51FBQ43668291-7B387724-3015-4326-B508-6E3C169DE962Q44436597-1D2F28C6-02B2-4D6B-8B91-D7170751A611Q44692424-1C25A2EC-B0DD-4C77-85E4-7817E345B527Q44831143-922B1F79-F40E-4F41-B7C9-A08E60D83D3BQ44974491-953ADF29-BEDA-4535-BC9F-43124D529EBBQ46038109-7DFDA53D-2802-4EBA-B57E-E28CDA8B2CF2Q46469528-C5B1C4F7-6E5A-4576-82A0-44B0FCF3520DQ46595642-6B25D5BF-6C46-48A8-B183-52CF6AADC3A9Q47160110-2F8CB580-BFB0-4DCE-8F7E-E009743FF829Q47845393-9E5F76EF-5ADC-401B-AEC9-E67F9C7FF353Q47911932-D548768F-F4D3-4BF1-B253-F109B1DF96B4Q48021570-2A03BF16-5FF1-4AB9-A655-CB49B79799FEQ48594222-FC5C5FD9-AE21-40E3-823C-5C77B0704F93Q48738973-FB118EAE-C43C-48AC-8439-AFA18985F480Q48878563-6F3CEAA8-6017-4172-B166-FE101529F953Q51028591-295428C1-8DEB-49CB-A7CC-1118B2BAE3B8Q51456630-22932586-BBB7-4173-AF05-3BC34FE8E7D0Q51483137-2DF66827-50EC-451B-999C-B30F0F8B8759Q52625055-69CFF57C-CDB2-4597-9B2F-F97B4FF13AE3Q53259493-FFDFAAB8-1817-430E-9A16-C5D5D9B081E4Q54148449-53089FFB-5850-45CC-929F-0D49D900CFFFQ56965098-6F87DBB8-66A2-4EAC-B6FE-A384385E122BQ59350259-85217556-BC96-4585-8A32-8217EB0EE4ABQ64086015-FDEE69E5-896B-4889-9C14-5E69FCC96F48Q64118893-3611F8BB-8DDE-4B52-ABE0-E23327922772Q64970851-937A50CB-9DAF-477B-9C47-FD097C57DE16Q73638583-04850953-FB07-4483-B36A-867D68573769Q73892932-FF4EA545-F46D-470A-8D7B-E9F2D954FED0
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Matthias F Kramer
@ast
Matthias F Kramer
@en
Matthias F Kramer
@es
Matthias F Kramer
@nl
type
label
Matthias F Kramer
@ast
Matthias F Kramer
@en
Matthias F Kramer
@es
Matthias F Kramer
@nl
prefLabel
Matthias F Kramer
@ast
Matthias F Kramer
@en
Matthias F Kramer
@es
Matthias F Kramer
@nl
P106
P21
P31
P496
0000-0002-3740-4733